tbuckley/cabot-search huggingface dataset:
THU0022 Systemic Lupus Erythematosus Increases Risk of Mortality among Patients with Acute Pancreatitis: Findings from A US National Hospital Registry
Authors: N.K. Mazumder, P. Trivedi, M. Mujib, B. Mehta, N. Mujib, W.S. Aronow, P. Efthimiou, T. Toronjadze, K. Beekman, J.H. Kim
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Acute pancreatitis is a rare presentation among systemic lupus erythematosus (SLE) patients. However, the association of SLE and clinical outcomes among acute pancreatitis has not been studied. <h3>Objectives</h3> To study the effect of SLE and in-hospital mortality among patients hospitalized with acute pancreatitis from a US national database. <h3>Methods</h3> We used the 2002-2010 Nationwide Inpatient Sample (NIS) databases to evaluate patients who were hospitalized for acute pancreatitis (ICD 9 code 577.0). Discharge weights were used to enable nationwide estimates. Of a total of approximately 80 million hospitalizations in NIS databases, 2.3 million were hospitalized for acute pancreatitis, of which, 14,553 (0.6%) had SLE. Multivariable logistic regression models were used to assess the effect of SLE on in-hospital mortality among these patients. <h3>Results</h3> Acute pancreatitis patients had a mean age of 53 (±18) years and 49% were women. Race distribution comprised of 50% Caucasians, 13% African-Americans and 10% Hispanics. In-hospital mortality occurred in 1.5% and 1.2% of patients with and without SLE respectively (unadjusted odds ratios, 1.26; 95% confidence intervals, 1.10-1.44; P=0.001). After controlling for patient risk factors, hospital characteristics, SLE patients independently conferred the higher adjusted odds of in-hospital mortality (adjusted odds ratios, 1.86; 95% confidence intervals, 1.62-2.14; P&lt;0.001). Acute pancreatitis patients with SLE had a longer mean length of stay (mean stay, 7 vs 5 days, P&lt;0.001) and a higher mean hospital charges ($33,984 vs. $27,126 P&lt;0.001). <h3>Conclusions</h3> In this nation-wide study, SLE was rare among acute pancreatitis hospitalizations and was independently associated with in-hospital mortality. SLE in acute pancreatitis was also associated with longer length of hospital stay and an increased hospital cost. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5410
Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
Authors: S.J. Antonia, J. Bendell, M. Taylor, E. Calvo, D. Jäger, F. de Braud, P.A. Ott, M.C. Pietanza, L. Horn, D.T. Le, M.A. Morse, J.A. López-Martin, P.A. Ascierto, O. Christensen, J.F. Grosso, J. Simon, C. Lin, J.P. Eder
Journal: Annals of Oncology (2015)
Prevention of Rubella by Gamma Globulin during an Epidemic in Barrow, Alaska, in 1964
Authors: Jacob A. Brody, John L. Sever, Gilbert M. Schiff
Journal: New England Journal of Medicine (1965)

DEPRESSION of the clinical symptoms of rubella by gamma globulin has been reported.1 2 3 Concern exists, however, since these results have not been consistent.1 , 4 , 5 Large doses of gamma globulin do not prevent infections of chicken pox,6 and possibly not hepatitis,7 although clinical symptoms may be depressed or delayed. Since rubella infection, with or without clinical symptoms, is a potential hazard to the developing fetus the recommended preventive dose of gamma globulin has steadily risen until recently it has become the practice to use 20 ml. for pregnant patients.5 With the advent of laboratory diagnostic procedures for isolation of rubella virus and . . .
Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance
Authors: Peter James Dyck, Phillip A. Low, Anthony J. Windebank, Safwan S. Jaradeh, Sylvie Gosselin, Pierre Bourque, Benn E. Smith, Kathleen M. Kratz, Jeannine L. Karnes, Bruce A. Evans, Alvaro A. Pineda, Peter C. O'Brien, Robert A. Kyle
Journal: New England Journal of Medicine (1991)

Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS) has been treated with plasma exchange, intravenous immune globulin, and chemotherapy, but the effectiveness of these treatments remains uncertain.
Quality of Quality Accounts: transparency of public reporting of Never Events in England. A semi-quantitative and qualitative review
Authors: Nazurah NN Abdul Wahid, Sarah H Moppett, Iain K Moppett
Journal: Journal of the Royal Society of Medicine (2016)

Objectives To describe the quality of reporting and investigation into surgical Never Events in public reports. Design Semi-quantitative and qualitative review of published Quality Accounts for three years (2011/2–2013/14). Data on Never Events were compared with previously collated Never Events rates. Quality of reported investigations was assessed using the London Protocol. Setting English National Health Service. Participants All English acute hospital trusts. Main outcome measures Quality of Never Event reporting. Results Quality Accounts were available for all Trusts for all three years, of which 342 referred to years when a surgical Never Event had occurred. A total of 125 of 342 (37%) accounts failed to report any or all Never Events that had occurred; 13/342 (4%) provided full disclosure; 197 (58%) reported that some investigation had taken place. Of these 197, 61 (31%) were limited in scope; 61 (31%) were categorised as detailed reports. Task and Technology factors were the commonest factor (103/211 (49%)) Identified in investigations, followed by Individual factors (48/211 (23%)). Team and Work environment factors were identified in 29/211 (14%) and 23/211 (11%), respectively. Organisational and Management 5/211 (2%) factors were rarely identified, and the Institutional context was never discussed. Conclusions Reporting of Never Events and their investigations by English NHS Trusts in their Quality Accounts is neither consistently transparent nor adequate. As with clinical error, the true root causes are likely to be organisational rather than individual.
Epidural Corticosteroid Injections for Sciatica Due to Herniated Nucleus Pulposus
Authors: Simon Carette, Richard Leclaire, Sylvie Marcoux, Frédéric Morin, Gilbert A. Blaise, André St.-Pierre, René Truchon, François Parent, Jacques Lévesque, Vincent Bergeron, Patrice Montminy, Caty Blanchette
Journal: New England Journal of Medicine (1997)

Although epidural corticosteroid injections are commonly used for sciatica, their efficacy has not been established.
Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure
Authors: Gerry Ligtenberg, Peter J. Blankestijn, P. Liam Oey, Inge H.H. Klein, Lioe-Ting Dijkhorst-Oei, Frans Boomsma, George H. Wieneke, Alexander C. van Huffelen, Hein A. Koomans
Journal: New England Journal of Medicine (1999)

Inhibition of angiotensin-converting enzyme (ACE) reduces the risk of cardiovascular problems in patients with chronic renal failure. This effect may be due in part to a decrease in sympathetic nervous activity, but no direct evidence of such an action is available.
PRELIMINARY RESULTS OF A PROSPECTIVE FEASIBILITY PILOT STUDY OF "GEMPOX" (GEMCITABINE, OXALIPLATIN, AND PACLITAXEL) IN PEDIATRIC AND ADULT PATIENTS WITH REFRACTORY OR RECURRENT CENTRAL NERVOUS SYSTEM (CNS) GERM CELL TUMORS (GCT): THE INTERNATIONAL CNS GCT CONSORTIUM TRIAL, CNS GCT-4
Authors: J. L. Finlay, Y. Liu, K. Haley, A. Erdreich-Epstein, T. Rushing, J. Grimm, K. E. Wong, E. Kiehna, M. D. Krieger, F. Gilles, B. Badie, M. D'Apuzzo, G. Dhall
Journal: Neuro-Oncology (2014)

BACKGROUND: The optimal management of patients with recurrent CNS GCT, especially those with non-germinomatous (mixed malignant) GCT (MMGCT), remains unclear. Preliminary results are presented on the response rate, toxicity and early outcomes of a re-induction regimen of gemcitabine, oxaliplatin and paclitaxel (GEMPOX) administered, in responsive patients, prior to myeloablative chemotherapy and autologous hematopoietic cell rescue (HDCx + AuHCR). METHODS: Since December 2004, 13 recurrent or refractory patients (12 MMGCT, 1 germinoma; 12 males; mean age 16.5 years, range 7-34 years) have been treated with up to 4 cycles of gemcitabine (800 mg/m2), oxaliplatin (100 mg/m2) and paclitaxel (170 mg/m2), administered on one day at 14 days intervals. RESULTS: Of 13 patients, five were treated on a preceding feasibility pilot with 1-3 cycles of GEMPOX, and seven have been formally enrolled on an ongoing prospective multi-center trial. Six patients achieved complete remissions (tumor marker and/or imaging studies), five achieved partial remissions and two developed progressive disease (PD) while on GEMPOX; one patient with PD after 1 cycle had pathologically confirmed malignant transformation to pure embryonal rhabdomyosarcoma.; the second patient, with pure pineal choriocarcinoma, progressed following the second cycle of GEMPOX. Eleven of the 13 patents subsequently underwent HDCx + AuHCR. Six of them subsequently received irradiation. Transient hepatotoxicity and pancytopenia were the most commonly observed toxicities. Other toxicities included: paclitaxel anaphylaxis (1), transient encephalopathy (1), peripheral neuropathy (1), hyperesthesia (4), mucositis (2) and electrolyte imbalances (3). Four of the 12 patients with MMGCT continue alive and disease-free for 8+ , 10+ , 14+ and 16+ months since discontinuation of all therapy. One patient (with pure yolk sac tumor) relapsed in a loco-regional extra-CNS location (cavernous and ethmoid/sphenoid sinuses) and remains alive with progressive disease on therapy now 12+ months post-HDCx + AuHCR. CONCLUSIONS: GEMPOX appears to be an effective re-induction regimen for patients with recurrent CNS MMGCT, with acceptable toxicities. The ongoing multi-center, international trial should confirm this and demonstrate the contribution of GEMPOX towards improved survival when followed by HDCx + AuHCR with or without further irradiation, in the setting of minimal residual disease. SECONDARY CATEGORY: Pediatrics.
1414 GUT MICROBIOTA REGULATES BILE ACID METABOLISM BY REDUCING THE LEVELS OF TAURO-BETAMURICHOLIC ACID, A NATURALLY OCCURRING FXR ANTAGONIST
Authors: S. Islam, J. Felin, S. Jantti, T. Hyotylainen, A. Wahlstrom, H.-U. Marschall, K. Bamberg, B. Angelin, M. Oresic, F. Bäckhed
Journal: Journal of Hepatology (2012)
Abstract 4054: Cell viability, apoptosis and ploidy analyses on a multi-laser, versatile flow cytometry analyzer – the EclipseTM
Authors: Yong Song
Journal: Cancer Research (2011)

Abstract Cell viability, apoptosis and ploidy analyses are essential tools in cancer research involving in vitro and in vivo studies. Assays for cell count and viability, apoptosis and cell cycle analysis are described in this report. Jurkat or Chinese hamster ovary cells were treated with various reagents such as anti-CD95, taxol, or brefaldin A to induce apoptosis. Apoptotic cells were labeled with Avenxin-V conjugated with Pacific Blue or FITC to determine externalization of phosphatidylserine to the cell surface. In combination with cell impermeant dyes, such as 7-aminoactinomycin D (7-AAD) or propidium iodide (PI), live, early apoptotic and late apoptotic/dead cells were labeled and analyzed on an Eclipse equipped with the 405 and 488 lasers. The iCyt® Eclipse TM is a compact bench top flow cytometry analyzer with an autoloader that supports a wide variety of multi-well plate and test tube formats. The system can be equipped with up to 4 lasers (405, 488, 561 and 642nm) and provides simultaneous detection of 5 colors, forward scatter, side scatter, electronic volume (EV) and cell concentration. The EV parameter enables accurate cell volume (size) measurement and allows normalization of fluorescent intensity on a per volume or surface area basis. Apoptotic cells were also detected with a phycoerythrin-labeled anti-active caspase 3 antibody after fixation and permeabilization. Cell cycle analysis with G0/G1, S and G2/M phase statistics plus cell size was achieved by labeling cells with 4′,6-diamidino-2-phenylindole (DAPI) in a cell permeabilization solution and analyzing on the Eclipse. Together with its intuitive software, the Eclipse flow cytometry analyzer provides a rapid, accurate and cost effective tool for most flow cytometry applications such as cell viability, apoptosis and cell cycle analysis. Note: For research use only. Not for use in diagnostic procedures. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4054. doi:10.1158/1538-7445.AM2011-4054
OC-022 Embolisation of inflow to allow safer liver resection—is more, better?
Authors: R Lochan, A Vallance, J French, R Charnley, B Jaques, J Rose, S White, D Manas
Journal: Gut (2012)

<h3>Introduction</h3> Portal vein embolisation (PVE) is now an established technique to increase the future liver volume/remnant (FLR) prior to liver resection. For those patients where hypertrophy is still considered insufficient complete uni-lateral embolisation incorporating both portal and hepatic artery embolisation (HAE) has been less frequently reported. The aim of this study was to evaluate the feasibility of sequential PV/HA embolisation to increase the FLR prior to liver resection. <h3>Methods</h3> All HPB patients are discussed at a weekly MDT meeting to decide on appropriate management decisions including the necessity for FLR augmentation. PVE is performed by initially obtaining a portogram by percutaneous trans-hepatic puncture. Selective embolisation of the necessary portal veins are then performed using a combination of coils and glue etc. Embolisation of Segment 4 PV branches are performed on a selective basis. HA embolisation is performed by mapping arterial inflow and selectively embolising the desired segments planned for resection while carefully preserving the FLR. The aim of this study was to evaluate the feasibility/safety of PVE with sequential HAE over a 5-year period (January 2006–May 2011). <h3>Results</h3> 50 patients (M:F = 38:12) underwent a right PVE; 33 (66%) progressed to liver resection. Reasons for inoperability (34%) following PVE (n=17) were (1) Small FLR, (n=6) all underwent HAE (with five proceeding to liver resection) (2) extra-hepatic disease (n=7) (3) progression of hepatic disease (n=4). The median FLR of those who progressed to resection following PVE, by CT volumetry, was 384.5 cc (330–490), significantly more than those who did not 237 cc (110–280) p=0.03. HAE increased the FLR by a further 99.8 cc (range 80.5–130 cc). An R0 resection was achieved in 25 patients (76%), including 4/5 (80%) of sequential patients. Following PVE and sequential embolisation; 9/33 (27%) and 3/5 (60%) suffered serious complications (Clavien-Dindo 3 or 4). There were six post operative deaths including 5/33 (15%) after PVE and 1 (20%) following sequential embolisation respectively. <h3>Conclusion</h3> PVE is an increasingly used technique to increase the FLR allowing a significant proportion of patients an R0 resection despite initially being considered inoperable. Nevertheless at least 20% of patients will also have progression of disease. Patients who do not achieve adequate hypertrophy can potentially have HA embolisation to increase the FLR by a further 100 cc but perhaps at the expense of increasing post-operative complications. <h3>Competing interests</h3> None declared.
Is Diaphragmatic Contractility Important?
Authors: Dudley F. Rochester
Journal: New England Journal of Medicine (1981)

IN this issue of the Journal, Aubier and his colleagues1 report that aminophylline in the usual therapeutic dose enhances the contractile force of the normal human diaphragm by 15 per cent and promptly reverses fatigue induced by inspiratory resistive loading. For an appreciation of the importance of their results, it is helpful to review some physiologic and clinical aspects of respiratory endurance and fatigue.The respiratory muscles constitute the "air pump" and are vital to life. The mechanical properties of the lungs and chest wall are such that the work of breathing is borne solely or primarily by the . . .
SAT0010 Generalization and Extrapolation of Treatment Effects from Clinical Studies in Rheumatoid Arthritis
Authors: S. C. Nair, W. Kievit, R. W. Janse, J. W. J. Bijlsma, F. P. J. Lafeber, J. Fransen, P. M. J. Welsing
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Randomized clinical trials (RCTs) are accepted as the 'gold standard' to evaluate the efficacy/effectiveness of treatment. However, generalizing results from RCTs to daily practice poses a challenge with treatment effectiveness often being different. Pragmatic clinical trials have been posed as a solution. <h3>Objectives</h3> To identify whether pragmatic clinical trials are indeed generalizable to clinical practice and investigate how efficacy estimates from RCTs can be translated into effectiveness estimates for daily practice populations. <h3>Methods</h3> Data from pragmatic clinical trials of the Utrecht Rheumatoid Arthritis Study Cohort and the observational Nijmegen inception cohort study with comparable inclusion criteria (RA &lt; 1 year disease duration and no prior DMARD use) were used. Patient characteristics were compared between the studies. The treatment effectiveness of MTX and Hydroxychloroquine both compared to the so-called Pyramid approach were compared between the pragmatic trials and observational data using a modified comprehensive cohort design analysis. Change from baseline in DAS28 and HAQ and EULAR good- and moderate response both at 6 months were the outcomes studied in the regression analyses. To study extrapolation of the treatment effect from Phase II/III clinical trials to clinical practice, published results from recent clinical trials evaluating biological treatment compared to control therapy were used. A metaregression analysis was performed to study the influence of population and treatment characteristics on ACR50% response at 6 months. Relative risk (RR) and risk difference (RD) were studied as outcome. <h3>Results</h3> Age, higher disease activity and response to treatment were higher in patients included in the pragmatic trial as compared to daily practice and rheumatoid factor positive patients were lower. DAS28 and HAQ generally improved more in trial patients as compared to daily practice. Using EULAR response as outcome, the relative effect of treatment (relative risk) was not found to be different. For extrapolating RCT results, glucocorticoid use, disease duration and co treatment with DMARD increased the RR in the study. Higher values of baseline DAS28 and HAQ decreased RD and the use of corticosteroids increased RD. <h3>Conclusions</h3> Pragmatic clinical trials might be directly generalizable only regarding relative treatment effects. In extrapolating RCT results to daily practice, population characteristics associated with disease activity, disease duration and treatment history or co-treatment need to be taken into account, regardless whether the treatment effect is expressed absolute or relative. Extrapolations of RCT results could also considerably impact costs-effectiveness results. <h3>Disclosure of Interest</h3> None Declared
Ga-67 Scintigraphy of Malignant Lymphoma of the Uterus
Authors: MITSURU TANIGUCHI, HAJIME YOKOTA, YOSHIMASA TOMITA, KOUTAROU HIGASHI, MANABU OUGUCHI, TETSUROU OKIMURA, ITARU YAMAMOTO
Journal: Clinical Nuclear Medicine (1996)

Primary uterine malignant lymphoma is frequently not prospectively diagnosed because of its rarity and nonspecific clinical findings. The authors present a case of primary uterine malignant lymphoma, in which ultrasonography, CT scan, and MRI revealed nonspecific findings, whereas Ga-67 scintigraphy showed intense uptake in the uterine mass that was highly suggestive of malignant lymphoma.
SAT0255 Predictive and protective role of adipokines in radiographic spinal progression in patients with ankylosing spondylitis:
Authors: D. Poddubnyy, E. Neumann, S. Junker, K. Frommer, H. Haibel, K. Conrad, M. Rudwaleit, U. Müller-Ladner, J. Sieper, U. Syrbe
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Adipokines are adipose-derived peptides with potent modulatory actions on immune cells and target tissues involved in ankylosing spondylitis (AS), including cartilage and bone. Nonetheless, there are nearly no data on relationship between adipokines and inflammation and new bone formation in AS. <h3>Objectives</h3> To investigate the association of adipokines with radiographic progression in the spine (new syndesmophytes formation or growth of the existing syndesmophytes) in patients with AS. <h3>Methods</h3> Altogether 86 patients with AS from the German Spondyloarthritis Inception Cohort (GESPIC) were included in the analysis. Radiographs of the lumbar and cervical spine performed at baseline and after 2 years of follow-up were centrally collected, digitized, and subsequently scored independently by two trained readers. Serum levels of C-reactive protein (CRP) were measured at baseline and every 6 months thereafter, a time-averaged value was calculated. Serum levels of adiponectin, resistin and visfatin were measure in baseline serum samples. Threshold for elevated/non-elevated levels of adipokines were chosen on the basis of median values. <h3>Results</h3> Radiographic spinal progression was noted in 28 patients (33%). Serum level of adiponectin was significantly lower and level of visfatin significantly higher in progressors as compared to patients without radiographic spinal progression over two years (table). Elevated level of adiponectin (&gt;12100 ng/ml) was protective regarding radiographic spinal progression: odds ratio (OR) for progression =0.22, 95%CI 0.08-0.61, p=0.003 that was also confirmed in the multivariate logistic regression analysis after adjustment for the baseline radiographic damage and CRP level: OR=0.18, 95%CI 0.06-0.59, p=0.004. Elevated level of visfatin (&gt;5.6 ng/ml) was, in contrast, predictive regarding radiographic spinal progression (OR=2.6, 95%CI 1.0-6.5, p=0.049), although the statistical significance was lost in the multivariate analysis. A predictive trend only was observed for resistin. There was no significant correlation of adiponectin and visfatin levels with acute phase reactants (CRP, erythrocyte sedimentation rate); resistin showed weak correlation with CRP (rho =0.23, p=0.03) and moderate correlation with visfatin (rho =0.54, p&lt;0.001), Importantly, in a subgroup of patients with persistent systemic inflammation (time averaged CRP &gt;6 mg/l) adiponectin retained its protective value regarding radiographic progression: OR=0.19, 95%CI 0.05-0.69, p=0.012. <h3>Conclusions</h3> Adiponectin plays a protective and visfatin a predictive role regarding radiographic spinal progression in AS, which seems to be independent from activity of systemic inflammation. <h3>Disclosure of Interest</h3> None Declared
A NOVEL THREE-DIMENSIONAL MYOCARDIAL STRAIN PARAMETERS ON RESTING SPECKLE TRACKING TTE COULD DETECT STABLE LV MYOCARDIAL ISCHEMIC SEGMENTS CONFIRMED BY INVASIVE FRACTIONAL FLOW RESERVE
Authors: Takeshi Nishi, Nobusada Funabashi, Koya Ozawa, Masayuki Takahara, Yoshihide Fujimoto, Hiroyuki Takaoka, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2016)